Identification | |
---|---|
Name | Calusterone |
Accession Number | DB01564 |
Type | small molecule |
Description | A 17-alkylated orally active androgenic steroid. A Schedule IV drug in Canada. |
Structure |
|
Categories (*) | |
Molecular Weight | 316.4776 |
Groups | illicit |
Monoisotopic Weight | 316.240230268 |
Pharmacology | |
Indication | An anabolic steroid which can theoretically aid in restauration and buildup of certain tissues, especially muscle. It is similar to synthetic testosterone and is still in early investigation. It was also investigated for use as a treatment for metastatic breast cancer. |
Mechanism of action | The effects of calusterone in humans most likely occur by way of two main mechanisms: by activation of the androgen receptor, and by conversion to estradiol and activation of certain estrogen receptors. Using testosterone as the prime example, free testosterone (T) is transported into the cytoplasm of target tissue cells, where it can bind to the androgen receptor, or can be reduced to 5α-dihydrotestosterone (DHT) by the cytoplasmic enzyme 5α-reductase. DHT binds to the same androgen receptor even more strongly than T, so that its androgenic potency is about 2.5 times that of T. The T-receptor or DHT-receptor complex undergoes a structural change that allows it to move into the cell nucleus and bind directly to specific nucleotide sequences of the chromosomal DNA. The areas of binding are called hormone response elements (HREs), and influence transcriptional activity of certain genes, producing the androgen effects. |
Absorption | Not Available |
Protein binding | Not Available |
Biotransformation | Not Available |
Route of elimination | Not Available |
Toxicity | Not Available |
Affected organisms |
|
Interactions | |
Drug Interactions | Not Available |
Food Interactions | Not Available |
Androgen receptor | |
---|---|
Name | Androgen receptor |
Gene Name | AR |
Pharmacological action | yes |
Actions | Not Available |
References |
|
DTHybrid score | 1.0315 |